ICO
Closed:

Novel Therapeutics and Druggable Targets for Non-malignant Hematological Diseases

An American pharmaceutical company with a focus on rare diseases is seeking novel therapeutics for non-malignant hematological diseases. Drug molecules that have a defined target, mechanism of action, and proven efficacy for a number of rare blood diseases are in scope for this campaign.

Approaches of Interest:

  • Diseases of interest include, but are not limited to, hereditary hemorrhagic telangiectasia, sickle cell disease, thalassemia, hereditary hemochromatosis, hereditary spherocytosis, diamond Blackfan anemia, Fanconi’s anemia, erythropoietic protoporphyria...

Opportunity types being sought:

  • Technology

  • Research Project

  • Spinout Company

  • Biotech Asset

To see the full details and submit your response please register now.

Benefits of registration:

  • Receive updates on the latest industry calls
  • Quickly and easily respond to calls via your dashboard
  • Build your academic profile

Opportunity types being sought:

  • Technology

  • Research Project

  • Spinout Company

  • Biotech Asset

An online matchmaking platform for university-industry collaboration. Learn More

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.